Development of Orally Disintegrating Tablets Based on a New Excipient - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Development of Orally Disintegrating Tablets Based on a New Excipient
The authors examine the effectiveness of an excipient comprised of mannitol, polyvinyl acetate, and crospovidone using model actives loperamide hydrogen chloride and caffeine.

Pharmaceutical Technology
Volume 32, Issue 11, pp. 66-70

There is a strong trend in the pharmaceutical industry toward developing orally disintegrating tablets because they have various benefits for the patient compared with regular tablets. These benefits include quick onset of action, ease of swallowing, and the ability to take the tablets without water (1). To achieve these benefits, highly functional excipients are required.

Figure 1: Property triangle of fast dispersible excipients. (ALL FIGURES ARE COURTESY OF BASF SE.)
Rapid dissolution, smooth mouth feeling, and excellent compressibility are three properties of fast dispersible excipients that are extremely important (see Figure 1). No single materials meet all these requirements, so Ludiflash (BASF SE, Ludwigshafen, Germany) was developed. This formulated mixture of mannitol, polyvinyl acetate, and crospovidone is a highly functional material that can be compressed directly and does not need complex and time-consuming processes such as mixer granulation, fluidized bed granulation, roller compaction, or freeze drying.

Aim of the study

The goal of this study was to investigate how orally disintegrating tablets containing the model actives loperamide hydrogen chloride (HCL) and caffeine can be developed. The effect of additional disintegrants and the impact of compression speed and tableting force were studied applying a direct compression process.


Table I: Tablet composition.
Materials. The following materials were used in the study: a fast dispersible excipient (Ludiflash, BASF SE) based on mannitol, polyvinyl acetate, and crospovidone; loperamide HCl (Selectchemie, Zurich, Switzerland); caffeine fine powder (BASF SE); sodium stearyl fumarate (Pruv, J. Rettenmaier & Söhne GmbH + Co. KG, Rosenberg, Germany); and crospovidone (Kollidon CL-SF, BASF SE).

Table II: Compression and tablet data from a compression force study at 40 rpm .
Experimental methods. Various formulations of the active ingredients and excipients were compressed into tablets (see Table I). All ingredients were blended in a Turbula blender (Bachofen, Uster, Switzerland) for 10 min and tableted on a rotary press (Korsch PH 106, Korsch AG, Berlin, Germany) into flat tablets of 8 mm (loperamide HCl), respectively, 10 mm diameter (caffeine) with a bevelled edge. The relative humidity (r. h.) inside the tablet press was adjusted < 20% r.h. The tableting speed was varied from 20 to 60 rpm and compression force from 1 to 16 kN.


Figure 2: Hardness, friability, and disintegration as a function of compressed force using loperamide tablets with 0% Kollidon CLSF. Kollidon CL-SF is a registered trademark of BASF SE. (ALL FIGURES ARE COURTESY OF BASF SE.)
The direct compression process was applicable to both model drugs with good results. The compression force study revealed that for loperamide HCl tablets, 3–5 kN (60–110 MPa) should be applied because in this range disintegrating tablets of sufficient hardness and low friability could be manufactured. A higher tableting pressure strongly reduces the porosity of the tablets and results in longer disintegration times (see Table II, Figures 2 and 3).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here